Reata Pharmaceuticals (NASDAQ:RETA) Downgraded by ValuEngine to “Hold”
A number of other equities analysts have also issued reports on RETA. Jefferies Financial Group raised their target price on Reata Pharmaceuticals from $128.00 to $254.00 and gave the stock a buy rating in a research note on Tuesday, October 15th. National Securities downgraded Reata Pharmaceuticals from a buy rating to a neutral rating in a research note on Wednesday, November 13th. LADENBURG THALM/SH SH reiterated a positive rating and set a $239.00 price target (up previously from $133.00) on shares of Reata Pharmaceuticals in a research note on Wednesday, October 16th. Cantor Fitzgerald increased their price objective on Reata Pharmaceuticals from $250.00 to $314.00 in a report on Wednesday, November 27th. Finally, BidaskClub upgraded Reata Pharmaceuticals from a buy rating to a strong-buy rating in a research note on Saturday, November 2nd. One investment analyst has rated the stock with a sell rating, two have given a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of Buy and a consensus price target of $255.63.
Reata Pharmaceuticals stock traded down $0.24 during mid-day trading on Tuesday, reaching $199.32. 431,100 shares of the company traded hands, compared to its average volume of 325,753. Reata Pharmaceuticals has a fifty-two week low of $47.50 and a fifty-two week high of $222.33. The company has a market capitalization of $6.08 billion, a price-to-earnings ratio of -69.45 and a beta of 2.64. The firm’s fifty day moving average is $198.69 and its two-hundred day moving average is $114.31.
In related news, CEO James Warren Huff sold 63,000 shares of the business’s stock in a transaction on Friday, September 27th. The shares were sold at an average price of $86.61, for a total transaction of $5,456,430.00. Following the completion of the transaction, the chief executive officer now directly owns 164,157 shares in the company, valued at $14,217,637.77. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Elaine Castellanos sold 3,000 shares of the company’s stock in a transaction on Monday, October 14th. The shares were sold at an average price of $105.00, for a total transaction of $315,000.00. Following the completion of the sale, the insider now directly owns 11,933 shares in the company, valued at $1,252,965. The disclosure for this sale can be found here. In the last three months, insiders have sold 101,000 shares of company stock valued at $10,879,910. 34.40% of the stock is currently owned by corporate insiders.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in RETA. Metropolitan Life Insurance Co NY boosted its stake in shares of Reata Pharmaceuticals by 8.7% in the third quarter. Metropolitan Life Insurance Co NY now owns 6,599 shares of the company’s stock worth $530,000 after buying an additional 528 shares during the last quarter. Point72 Asset Management L.P. raised its position in Reata Pharmaceuticals by 13.5% during the third quarter. Point72 Asset Management L.P. now owns 360,088 shares of the company’s stock valued at $28,911,000 after acquiring an additional 42,788 shares in the last quarter. California State Teachers Retirement System lifted its holdings in Reata Pharmaceuticals by 1.0% in the third quarter. California State Teachers Retirement System now owns 31,272 shares of the company’s stock valued at $2,511,000 after acquiring an additional 322 shares during the period. Stifel Financial Corp lifted its holdings in Reata Pharmaceuticals by 1.7% in the third quarter. Stifel Financial Corp now owns 31,072 shares of the company’s stock valued at $2,489,000 after acquiring an additional 519 shares during the period. Finally, Virtu Financial LLC purchased a new stake in Reata Pharmaceuticals in the 3rd quarter worth approximately $569,000. Institutional investors and hedge funds own 60.04% of the company’s stock.
About Reata Pharmaceuticals
Reata Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (Bard) for the treatment of patients with chronic kidney disease caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; and omaveloxolone that is Phase II clinical trial for the treatment of patients with Friedreich's ataxia It is also developing RTA 901, which completed Phase 1 clinical trials for the treatment of orphan neurological indications; and RORgT Inhibitors that are in the preclinical development phase for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases.
Featured Article: How does inflation affect different investments?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.